Overview

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study purpose is to evaluate the effect of QAB149 - NVA237 vs. QAB149 on static lung hyperinflation.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Glycopyrrolate
Lactitol